Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin DR for Active Moderate Crohn's Disease
NCT02240108Phase 3Terminated
- Sponsor
- Valeant Pharmaceuticals
- Start
- Oct 2014
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rifaximin in Crohn's disease, sponsored by Valeant Pharmaceuticals. Started Oct 2014; status: terminated.
02
Drugs
rifaximin
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02240108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02240108.